Keep up the pace of drug development evolution and expenditure

Da-Yong Lu, Ting-Ren Lu, Enhong Chen, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Min Huang, Hong ZhuCancer 2018 · DOI

Abstract

Drug development is a pillar industry for many developed countries, yet highly adventurous more recently. Correspondingly, new anticancer drug discovery, development and manufacture norm have been consistently evolving during the past decades. The techniques and tumor models for drug screening create a slow progression of anticancer drug discovery and developments. To promote the efficiency of anticancer drug developments, keeping up the pace of modern anticancer drug development evolution and advances is indispensable. A lot of disciplines need to be noticed and updated. This article addresses important factors affecting the efficiency of anticancer drug developments—including possible innovations of drug screening models, incorporation of latest scientific progresses, cutting-edge technology utility, emerging clinical therapeutic norms (such as personalized medicine and precision medicine) and so on.

Introduction: The Industry Bottleneck

Despite decades of intensive research, cancer remains a leading cause of global mortality, primarily due to drug resistance and a critical lack of effective antimetastatic therapies. The pharmaceutical industry currently faces a significant "bottleneck": the cost of bringing a single anticancer drug to market has ballooned to between $1 billion and $2 billion USD. Despite this massive investment, many promising agents fail in late-stage clinical trials. This review argues that this stagnation is largely due to a disconnect between simplified preclinical models and the complex clinical reality of human cancer.

The Evolution of Drug Screening Models

The core challenge in drug discovery is that traditional screening often relies on simplified cell lines that have lost their original characteristics through long-term laboratory passage. These models fail to account for the dynamic nature of metastasis—responsible for 90% of cancer deaths—and the critical role of the tumor stroma (connective tissue).

To break the current bottleneck, the field must transition from basic anti-proliferative screens to comprehensive tumor models that include human xenografts and stroma-inclusive environments. Historically, model selection has dictated the type of drugs discovered; moving toward more complex systems is essential for identifying the next generation of antimetastatic therapies.

The evolution of anticancer drug screening models from simple murine leukemia cells to comprehensive tumor models and clinical therapeutic options.

Technological Integration and Precision Medicine

The transition from basic observation to high-tech diagnostics is a hallmark of modern oncology. This includes the integration of Next-Generation Sequencing (NGS), advanced imaging (PET/MRI), and high-resolution chromatography (HPLC-MS). These tools facilitate the shift toward Individualized Cancer Therapy (ICT) and Precision Medicine, where pharmacogenetics and drug sensitivity testing (DST) allow clinicians to match specific therapies to the unique genetic profile of a patient's tumor.

The progression of cancer research technology from tumor models to non-invasive imaging and genetic analysis.

Critical Insights: Stroma and Metastasis

A major point of contention in modern drug development is the "stroma controversy." A tumor is a complex ecosystem, not just a mass of malignant cells. Neglecting the tumor stroma in drug screening is a primary reason why compounds successful in the lab often fail in patients. Furthermore, there is a severe shortage of wide-spectrum antimetastatic drugs. Future research must prioritize organ-specific metastatic models (e.g., bone, brain, or liver) over general pulmonary colony models to improve clinical relevance.

Economic Realignment and Global Responsibility

The staggering financial risk associated with drug development necessitates a global realignment. The authors suggest that "BRICS" and other developing nations should assume greater pharmaceutical responsibility. By utilizing their vast patient resources for more cost-effective clinical evaluations, these regions can help reduce global development costs and accelerate the delivery of new treatments.

Limitations and Future Directions

Despite these advancements, several hurdles remain. Many compounds that inhibit metastasis in animal models still fail to demonstrate survival benefits in human trials. Additionally, regulatory inconsistencies across borders and the inherent complexity of Cancer Stem Cells (CSCs)—which are often missed in standard screens but vital for resistance—continue to hinder progress.

Future work must focus on integrating mathematical and computational networks to mitigate investment risks. By adopting a "jigsaw" approach—integrating disparate pieces of biological, pathological, and genomic data—the scientific community can build a more holistic and effective framework for cancer intervention.

Summary updated

Abstract

Drug development is a pillar industry for many developed countries, yet highly adventurous more recently. Correspondingly, new anticancer drug discovery, development and manufacture norm have been consistently evolving during the past decades. The techniques and tumor models for drug screening create a slow progression of anticancer drug discovery and developments. To promote the efficiency of anticancer drug developments, keeping up the pace of modern anticancer drug development evolution and advances is indispensable. A lot of disciplines need to be noticed and updated. This article addresses important factors affecting the efficiency of anticancer drug developments-including possible innovations of drug screening models, incorporation of latest scientific progresses, cutting-edge technology utility, emerging clinical therapeutic norms (such as personalized medicine and precision medicine) and so on.
BibTeX
@inproceedings{lu2018keep,
  author = {Da-Yong Lu and Ting-Ren Lu and Enhong Chen and Nagendra Sastry Yarla and Bin Xu and Jian Ding and Min Huang and Hong Zhu},
  title = {{Keep up the pace of drug development evolution and expenditure}},
  booktitle = {Cancer},
  year = {2018},
  doi = {10.15761/crr.1000165},
}
Figure